Envestnet Portfolio Solutions Inc. acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,732 shares of the company's stock, valued at approximately $291,000.
Other institutional investors have also added to or reduced their stakes in the company. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth $27,000. GAMMA Investing LLC lifted its holdings in Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock worth $108,000 after purchasing an additional 220 shares in the last quarter. Blue Trust Inc. boosted its stake in Prestige Consumer Healthcare by 24.8% in the 4th quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock worth $158,000 after purchasing an additional 435 shares during the period. KBC Group NV boosted its stake in Prestige Consumer Healthcare by 28.3% in the 4th quarter. KBC Group NV now owns 2,048 shares of the company's stock worth $160,000 after purchasing an additional 452 shares during the period. Finally, Longboard Asset Management LP purchased a new position in Prestige Consumer Healthcare during the 4th quarter valued at about $201,000. 99.95% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.60% of the company's stock.
Prestige Consumer Healthcare Trading Up 1.2 %
Shares of PBH traded up $0.98 during trading hours on Monday, hitting $86.07. The company had a trading volume of 563,261 shares, compared to its average volume of 272,465. The firm has a market cap of $4.26 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.69 and a beta of 0.46. The stock's 50 day moving average price is $83.45 and its 200 day moving average price is $79.17. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare Inc. has a 52-week low of $62.35 and a 52-week high of $90.04.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on PBH shares. Oppenheimer increased their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a research note on Monday, December 9th. Royal Bank of Canada raised their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research report on Friday, March 21st. Finally, StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday, March 18th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of "Moderate Buy" and a consensus price target of $93.33.
Get Our Latest Analysis on PBH
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Recommended Stories
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
